Management of Pulmonary Arterial Hypertension Exacerbation

Initial Assessment and Stabilization

Patients experiencing PAH exacerbation should be immediately referred to a specialized pulmonary hypertension center due to the complexity of management 1, 2
Assess for clinical evidence of right ventricular failure, which indicates worse prognosis (peripheral edema, jugular venous distension, hypotension) 3
Evaluate hemodynamic parameters including cardiac index, right atrial pressure, and mixed venous oxygen saturation 3
Monitor vital signs, oxygen saturation, and obtain baseline arterial blood gases to assess for respiratory alkalosis pattern and hypoxemia 3

The European Society of Cardiology recommends initiating intravenous epoprostenol for patients with severe PAH exacerbation (NYHA/WHO functional class IV) 4
Continue background therapy including oral anticoagulants (if no contraindications exist), diuretics for management of fluid retention and right heart failure, supplemental oxygen to maintain saturation >90%, and digoxin for refractory right heart failure and/or supraventricular arrhythmias 4, 5

For patients who previously demonstrated positive acute vasoreactivity, the American College of Chest Physicians recommends continuing calcium channel blockers if they have shown sustained response 6, 4
For non-vasoreactive patients or those who failed calcium channel blocker therapy, initiate or optimize prostanoid therapy (epoprostenol IV) 6, 4
Consider combination therapy with endothelin receptor antagonists (bosentan) and/or PDE-5 inhibitors 4, 5

Monitor for clinical improvement using parameters such as hemodynamic measurements (cardiac index, PVR, right atrial pressure), exercise capacity (6-minute walk test when stabilized), WHO functional class improvement, and BNP/NT-proBNP levels 3
If inadequate response to initial therapy, escalate to combination therapy targeting multiple pathways 5, 3
Consider referral for lung transplantation evaluation for patients with NYHA/WHO functional class III and IV symptoms who are deteriorating despite maximal medical therapy 6, 7

Recognize that patients with PAH associated with connective tissue disease may have different response patterns to therapy compared to idiopathic PAH 2, 5
For patients requiring surgery during PAH exacerbation, coordinate care at a pulmonary hypertension center with careful monitoring of clinical status, oxygenation, and hemodynamics 8

Parameters indicating worse prognosis include clinical evidence of right ventricular failure, rapid progression of symptoms, syncope, WHO functional class IV, short 6-minute walk distance (<300m), elevated and rising BNP/NT-proBNP levels, presence of pericardial effusion on echocardiography, and right atrial pressure >15 mmHg or cardiac index <2.0 L/min/m² 3
Schedule close follow-up after exacerbation to adjust therapy based on clinical response and reassess disease severity 2, 5